Selective PI3K Deals Abound, But is Targeted Always Best?
While early efforts to target phosphoinositide-3 kinase (PI3K) involved pan-inhibition, biotechs like Intellikine Inc. and Calistoga Pharmaceuticals Inc. differentiated themselves by selectively targeting the alpha, beta, delta and/or gamma isoforms of PI3K rather than hitting the whole family.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST